Position in URGN
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$270,848
New position
Shares Held
7,360
first reported quarter
Ownership
0.015%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#132
of 189 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Kathmere Capital Management, LLC holds $2,116,993 across 8 Biotechnology names. URGN ranks #4 (12.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SXTP |
60 Degrees Pharmaceuticals, Inc.
|
265,100 | $466,576 | |
| 2 | ARGX |
Argenx SE
|
366 | $339,563 | |
| 3 | AUPH |
Aurinia Pharmaceuticals Inc.
|
17,461 | $296,313 | |
| 4 | URGN |
UroGen Pharma Ltd.
This page
|
7,360 | $270,848 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
529 | $262,770 | |
| 6 | PBYI |
Puma Biotechnology, Inc.
|
31,172 | $252,804 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
868 | $209,161 | |
| 8 | BDTX |
Black Diamond Therapeutics, Inc.
|
10,248 | $18,958 |
All Filings in URGN
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $270,848 | 7,360 | Shares | Sole | 2026-07-29 | |
| No filing history on record for this holder in this stock. | ||||||